Security
Processa Pharmaceuticals, Inc. Common Stock · PCSA
PCSANASDAQCommon stockHistorical · closed Oct 19, 2026CIK 1533743Updated Nov 6, 2026
Name history
Heatwurx, Inc. · through Oct 20, 2017
Current security for this SEC filerPCSA · NASDAQ
PCSA price & chart
Historical security
This listing closed Oct 19, 2026. Live provider charts are shown only for current listings.
Current security: PCSA
About the company
We are a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (“NGC”) small molecules, two of which are in, or have completed, Phase 2 trials, and one is in pre-clinical development.
In the news
Recent filings
DEFA14A filing
DEFA14A filing
Other Events
Items 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01, 9.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 7,584,576Source | 4,942,152Source | 2,069,562Source | 8,181,789Source | 7,600,976Source | 4,520,974Source | 4,809,574Source | 9,944,732Source | 7,813,567Source | 3,229,289Source | 5,786,643Source | 8,619,851Source |
| Property, Plant and Equipment, NetUSD | 4,113Source | 5,317Source | 3,210Source | — | 2,276Source | 3,511Source | — | 2,415Source | 3,812Source | 5,016Source | 2,554Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,308,420Source | 2,891,464Source | 196,325Source | 6,936,620Source | 5,571,120Source | 1,691,043Source | 2,897,072Source | 8,920,363Source | 5,536,955Source | 1,191,325Source | 4,706,197Source | 6,503,595Source |
| Assets, CurrentUSD | 6,586,762Source | 4,838,139Source | 2,066,352Source | 7,153,821Source | 7,477,974Source | 1,938,406Source | 3,757,886Source | 9,800,293Source | 5,670,874Source | 1,873,619Source | 5,632,497Source | 8,386,729Source |
| Prepaid Expense and Other Assets, CurrentUSD | 278,342Source | 1,946,675Source | 1,398,024Source | 217,201Source | 1,906,854Source | 247,363Source | 860,814Source | 857,635Source | 133,919Source | 682,294Source | 926,300Source | 1,883,134Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | 24,318Source | — | — | 47,737Source | — | — | 70,677Source | 146,057Source | 227,587Source |
| Other Assets, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | 5,535Source | 5,535Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,750,978Source | 1,221,367Source | 2,386,903Source | 2,074,581Source | 1,577,312Source | 1,980,093Source | 1,282,966Source | 1,061,366Source | 2,236,253Source | 1,533,118Source | 797,484Source | 1,149,110Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 5,287Source | 327Source | 279Source | 4,029Source | 287Source | 269Source | 527Source | 286Source | 257Source | 371Source | 129Source | 1,614Source |
| Retained Earnings (Accumulated Deficit)USD | -97,424,095Source | -84,490,491Source | -107,425,706Source | -93,987,522Source | -81,105,788Source | -104,160,212Source | -90,053,604Source | -78,095,462Source | -100,783,033Source | -87,219,199Source | -75,369,081Source | -64,247,561Source |
| Stockholders' Equity Attributable to ParentUSD | 5,833,598Source | 3,720,785Source | -317,341Source | 6,107,208Source | 6,023,664Source | 2,540,881Source | 3,526,608Source | 8,883,366Source | 5,577,314Source | 1,696,171Source | 4,989,159Source | 7,470,741Source |
| Additional Paid in Capital, Common StockUSD | 103,552,406Source | 88,510,949Source | 107,108,086Source | 100,390,701Source | 87,429,165Source | 106,700,824Source | 93,879,685Source | 87,278,542Source | 106,660,090Source | 89,214,999Source | 80,658,111Source | 72,016,688Source |
| Liabilities and EquityUSD | 7,584,576Source | 4,942,152Source | 2,069,562Source | 8,181,789Source | 7,600,976Source | 4,520,974Source | 4,809,574Source | 9,944,732Source | 7,813,567Source | 3,229,289Source | 5,786,643Source | 8,619,851Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 1,750,978Source | 1,219,199Source | 2,386,903Source | 2,074,581Source | 1,551,664Source | 1,980,093Source | 1,282,966Source | 1,010,666Source | 2,236,253Source | 1,532,631Source | 730,579Source | 998,556Source |
| Operating Lease, Liability, CurrentUSD | — | 88,777Source | — | 21,832Source | 87,495Source | — | 44,593Source | 84,878Source | — | 66,905Source | 83,649Source | 78,896Source |
| Accounts Payable, CurrentUSD | 727,172Source | 711,710Source | 1,659,438Source | 785,754Source | 953,086Source | 840,370Source | 552,560Source | 455,368Source | 1,056,796Source | 880,880Source | 311,617Source | 327,548Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | 21,831Source | — | — | 44,593Source | — | — | 66,905Source | 150,554Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,023,806Source | 412,813Source | 727,465Source | 1,263,243Source | 505,397Source | 1,139,723Source | 680,747Source | 465,618Source | 1,179,457Source | 578,731Source | 146,274Source | 403,061Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 95,963Source | 227,711Source | 857,550Source | 629,514Source | 1,060,339Source | 8,828,713Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -216,426Source | -328,320Source | 175,916Source | 569,263Source | -15,931Source | 108,643Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,590,695Source | -2,729,848Source | -11,385,195Source | -11,245,042Source | -8,063,346Source | -9,605,143Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -500,000Source | — | -850,000Source | -3,244Source | -2,776Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 3,244Source | 2,776Source | — |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 320Source | 1,439Source | 10,404Source | 15,902Source | — | 88,843Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 244,783Source | 4,435,595Source | 16,580,825Source | 7,733,414Source | 6,268,724Source | -388,843Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,845,912Source | 1,705,747Source | 4,345,630Source | -3,514,872Source | -1,797,398Source | -9,993,986Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 5,162Source | 1,880Source | 5,607Source | 1,204Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 303,047Source | 154,191Source | 92,105Source | 203,251Source | 95,963Source | 227,711Source | 857,550Source | 629,514Source | 2,371,214Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | — | — | 115,613Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 788,495Source |
| DepreciationUSD | — | — | — | — | — | — | 301Source | 301Source | 1,204Source | 782Source | 222Source | — |
| General and Administrative ExpenseUSD | — | — | 1,827,197Source | 1,137,328Source | 1,686,261Source | 1,503,497Source | 1,522,005Source | 1,258,450Source | 6,178,168Source | 4,782,060Source | 5,657,543Source | 8,763,058Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 7,268,143Source |
| Investment Income, InterestUSD | — | — | — | 40,150Source | — | — | 13,859Source | 12,585Source | 109,491Source | 201,088Source | 335,541Source | 101,202Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,436,573Source | -3,384,703Source | -3,265,494Source | -3,933,918Source | -3,377,179Source | -2,834,405Source | -13,563,834Source | -11,850,118Source | -11,121,520Source | -27,424,229Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,436,573Source | -3,384,703Source | -3,265,494Source | -3,933,918Source | -3,377,179Source | -2,834,405Source | -13,563,834Source | -11,850,118Source | -11,121,520Source | — |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 81,530Source | 85,518Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 245,103Source | 4,438,570Source | 16,597,831Source | 7,763,079Source | 6,321,470Source | 6,400,000Source |
| Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Operating Income (Loss)USD | — | — | -3,488,843Source | -3,424,853Source | -2,336,138Source | -3,950,783Source | -3,331,214Source | -2,846,990Source | -13,988,505Source | -12,051,206Source | -11,457,061Source | -27,525,431Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | -3,377,179Source | -2,834,405Source | -13,563,834Source | -11,850,118Source | -11,121,520Source | -27,424,229Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,436,573Source | -3,384,703Source | -3,265,494Source | -3,933,918Source | -3,377,179Source | -2,834,405Source | -13,563,834Source | -11,850,118Source | -11,121,520Source | -27,424,229Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.07Source | -1.03Source | -1.19Source | -6.26Source | -1.29Source | -7.58Source | -10.36Source | -3.87Source | -8.48Source | -1.7Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.07Source | -1.03Source | -1.19Source | -6.26Source | -1.29Source | -7.58Source | -10.36Source | -3.87Source | -8.48Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 47,525,522Source | 3,275,998Source | 2,750,742Source | 628,796Source | 2,623,143Source | 373,967Source | 1,309,271Source | 3,059,906Source | 1,311,572Source | 16,109,291Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 47,525,522Source | 3,275,998Source | 2,750,742Source | 628,796Source | 2,623,143Source | 373,967Source | 1,309,271Source | 3,059,906Source | 1,311,572Source | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 788,495Source |
| General and Administrative ExpenseUSD | — | — | 1,827,197Source | 1,137,328Source | 1,686,261Source | 1,503,497Source | 1,522,005Source | 1,258,450Source | 6,178,168Source | 4,782,060Source | 5,657,543Source | 8,763,058Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -13,204,883Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | 40,150Source | — | — | 13,859Source | 12,585Source | 109,491Source | 201,088Source | 335,541Source | 101,202Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,436,573Source | -3,384,703Source | -3,265,494Source | -3,933,918Source | -3,377,179Source | -2,834,405Source | -13,563,834Source | -11,850,118Source | -11,121,520Source | — |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 81,530Source | 85,518Source |
| Other IncomeUSD | — | — | — | — | — | — | — | — | 20,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 5,799,518Source | 11,494,230Source |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-299388
Registration 333-287997
- Gross proceeds
- 6998631.0
- Net proceeds
- 6508631.0
- Deal price
- 0.25
- Shares
- 27994524
- Offering price
- $0.2500
- Ticker
- PCSA
Registration 333-283986
- Net proceeds
- 4679679.0
- Deal price
- 0.615
- Offering price
- $0.61500
- Ticker
- PCSA
Filing attachments
ef20084860_ex99-1.htm · DEFA14A · 2026-11-05
Exhibit 99.1 Dear Processa Stockholder, In July, Processa acquired Vidya Therapeutics and completed a concurrent private placement financing of approximately $200 million supported by leading institutional healthcare investors. This transaction established a new strategic direction for the company focused on advancing differentiated therapeutic programs for immunological and inflammatory (I&I) diseases, led by VT-7208, Vidya’s lead investigational product candidate. We believe this combinati…
Read attachment ↗ef20084860_ex99-1.htm · 8-K · 2026-11-05
Exhibit 99.1 Dear Processa Stockholder, In July, Processa acquired Vidya Therapeutics and completed a concurrent private placement financing of approximately $200 million supported by leading institutional healthcare investors. This transaction established a new strategic direction for the company focused on advancing differentiated therapeutic programs for immunological and inflammatory (I&I) diseases, led by VT-7208, Vidya’s lead investigational product candidate. We believe this combinati…
Read attachment ↗ef20084865_ex99-1.htm · 8-K · 2026-11-04
Exhibit 99.1 Processa Pharmaceuticals Announces Key Leadership Appointments VERO BEACH, FL, November 4, 2026 - Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory diseases, today announced key leadership appointments to support the Company’s next phase of growth: Gregory J. Flesher, Chief Operating Officer Craig Coburn, Ph. D., Executive Vice P…
Read attachment ↗ef20084530_ex99-1.htm · 8-K · 2026-10-29
Exhibit 99.1 Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics U.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria; additional Phase 2 studies planned in food allergy and relapsing multiple sclerosis Company expands pipeline through research collaboration of a novel, oral macrocyclic peptide-based neonatal Fc receptor antagonist program from Generian Pharmaceuticals Sheila Gujrathi, M.D., appoi…
Read attachment ↗ny20083513x1_ex107.htm · S-3 · 2026-10-09
Exhibit 107 CALCULATION OF FILING FEE TABLES S-3 (Form Type) Processa Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate…
Read attachment ↗ex99-1.htm · 8-K · 2026-07-29
EX-99.1 6 ex99-1.htm EX-99.1 Exhibit 99.1 PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS Acquisition brings into Processa’s pipeline Vidya’s lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton’s tyrosine kinase inhibitor (BTKi) designed to overcome the efficacy and safety limit…
Read attachment ↗